IFF Expands the Launch of Industry-leading Poultry Solutions in the EU
IFF has received EU-wide regulatory approval for two new feed solutions for poultry: Axtra® XAP and Syncra® AVI. These products, developed by Danisco Animal Nutrition & Health, aim to improve poultry performance and reduce feed costs.
Axtra® XAP is a blend of xylanase, amylase, and protease enzymes, which enhances nutrient absorption and allows for flexible dietary formulations. Syncra® AVI combines enzymes and probiotics to optimize gut health and overall productivity. These solutions are also available in North America, South Africa, and Asia Pacific.
- EU-wide regulatory approval for Axtra® XAP and Syncra® AVI.
- Axtra® XAP improves energy efficiency and reduces feed costs.
- Syncra® AVI optimizes gut health and maximizes poultry performance.
- Availability in major markets like North America, South Africa, and Asia Pacific.
- No concrete financial or performance data provided to support claims.
The launch of Axtra® XAP and Syncra® AVI in the EU represents a significant strategic expansion for IFF's Health & Biosciences division. From a market perspective, the approval and deployment of these feed solutions across a broad geographic area amplify the company's growth potential. These products are positioned to address critical needs in modern poultry production, including cost reduction and improved flock health, which are resonant themes within the industry.
Axtra® XAP offers economic benefits by enhancing feed efficiency and reducing overall feed costs, which is considerable in a sector where feed expenses constitute a substantial part of operational costs. Meanwhile, Syncra® AVI supports the long-term trend towards antibiotic reduction, aligning with regulatory moves and consumer preferences for healthier and more sustainable poultry production.
Given these solutions are already available in established markets like North America and Asia Pacific, their EU launch can be seen as leveraging proven success elsewhere to penetrate a new regional market. The potential increase in market share and revenue streams from EU poultry producers could be material for IFF's financial performance in the upcoming quarters.
From a financial standpoint, the EU authorization for Axtra® XAP and Syncra® AVI has several implications. The immediate effect is the potential to boost IFF’s revenue in the short term through increased product sales. These products are designed to provide economic advantages to poultry producers, which can translate to a competitive pricing strategy for IFF while still offering substantial value to customers.
Moreover, this development can strengthen IFF's position in the agricultural feed market, potentially enhancing its pricing power and market penetration in the EU. This could lead to higher profit margins and improved earnings in the long term, although investors should monitor the actual adoption rates and the competitive landscape closely.
Additionally, integrating these innovative solutions into the EU market may stimulate further investments in R&D and product enhancement, supporting sustained growth. However, investors should remain cautious of regulatory risks and the variability in acceptance rates across different markets within the EU.
Axtra® XAP and Syncra® AVI represent advanced nutritional interventions for the poultry industry. Axtra® XAP’s multi-enzyme blend optimizes nutrient absorption, which can lead to better bird growth rates and feed conversion ratios. This directly impacts the profitability of poultry operations by lowering feed costs and increasing efficiency, which is particularly critical in the high-volume, low-margin poultry sector.
Syncra® AVI's combination of enzymes and probiotics targets gut health, a vital factor not only for productivity but also for reducing disease incidence and dependency on antibiotics. The concept of nutribiosis emphasized by IFF aligns with current scientific understanding that a healthy gut microbiome enhances overall animal health and performance. These aspects can provide a long-term competitive advantage to producers who adopt these technologies, aligning with sustainability and ethical farming practices.
This regulatory approval in the EU further underscores the credibility and scientific robustness of these products, potentially making them a benchmark for future feed solutions.
Two newly approved solutions, Axtra® XAP and Syncra® AVI deliver superior technical and economic performance improvements in poultry feeds
"Obtaining full EU authorization empowers us to unleash the remarkable potential of these two exceptional in-feed products to poultry producers across the region," said Jose Luis Ecija Roux, marketing director EMEA, Danisco Animal Nutrition & Health. "Axtra® XAP and Syncra® AVI have demonstrated their pivotal role in advanced feed strategies, and we look forward to helping our customers in maximizing this unprecedented opportunity."
Axtra® XAP - fuels efficiency and reduces costs
Axtra® XAP, a high-performance xylanase, amylase and protease enzyme combination, increases energy efficiency and improves bird performance in both corn-based and mixed-grain diets. Through optimized nutrient availability, this unique feed solution enables greater flexibility in dietary formulations, significantly reduces feed costs and improving profitability1. Additionally, Axtra® XAP allows producers to adapt their operations to meet consumer demands and industry trends, including free-range production and the use of all-vegetable dietary ingredients.
Syncra® AVI, a gut health revolution
Syncra® AVI combines two proven technologies – enzymes and probiotics – known to optimize gut health and maximize performance in poultry production. The synergistic combination of enzymes and probiotics in Syncra® AVI helps to create a favorable nutribiotic state that supports flock health, wellness, and productivity. Nutribiosis is the interplay between nutrition, microbiome, gut and immune function where they interact in the host.
The EU is the latest region to launch Axtra® XAP and Syncra® AVI. Both solutions are currently available in major markets around the world including
1 Internal experimental data |
About Danisco Animal Nutrition & Health
Danisco Animal Nutrition & Health, part of IFF is an industry leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, essential oils and probiotics. Through the lens of nutribiosis, IFF invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. Danisco Animal Nutrition & Health capabilities are underpinned by the quality and quantity of our trials, including over 100,000 guts sampled from over 600 farms, investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit animalnutrition.iff.com
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.
©2024 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Contact:
Denisse Gaudin
Marketing Communications Manager
+31615102508
Denisse.gaudin@iff.com
SOURCE IFF
FAQ
What are Axtra® XAP and Syncra® AVI by IFF?
When did IFF announce EU approval for Axtra® XAP and Syncra® AVI?
What benefits do Axtra® XAP and Syncra® AVI offer to poultry producers?
In which markets are Axtra® XAP and Syncra® AVI available?
How do Axtra® XAP and Syncra® AVI align with current industry trends?
